Berberine derivatives and preparation methods and applications thereof
By synthesizing berberine derivatives, the steric hindrance and biomembrane permeability problems of berberine in nucleic acid delivery systems were solved, achieving strong nucleic acid carrying capacity and brain-targeting properties, and constructing a safe and efficient nucleic acid drug delivery system.
Patent Information
- Application Number
- CN202311649434.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-04
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-12-04
AI Technical Summary
The development of berberine as a nucleic acid delivery carrier material in existing technologies has not been fully explored, especially the influence of its steric hindrance effect on ionization properties and its biomembrane permeability, which limits its application in nucleic acid delivery systems.
Berberine derivatives were designed and synthesized, and ionizable lipids were formed through specific structural modifications, including isoquinoline ring fusion backbone and specific alkyl or PEG modifications. Lipid nanoparticles with nucleic acid delivery capabilities were formed by using appropriate synthetic methods such as dissolving in solvent and adding catalysts.
Berberine derivatives exhibit strong nucleic acid carrying capacity, improve nucleic acid stability, promote lysosomal escape, and possess specific brain-targeting properties, enabling safe and efficient delivery of nucleic acid drugs.
Smart Images

Figure CN117659003B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of preparation of berberine derivatives, and relates to berberine derivatives and preparation methods and applications thereof. Background Art
[0002] In recent years, small molecule natural products have shown their unique effectiveness in drug development and drug delivery. Representative examples include: the complex formed by the monoclonal antibody Herceptin and the flavonoid (-)-epigallocatechin-3-O-gallate (EGCG) can be used for anti-cancer; the modification of therapeutic proteins or peptides with phenolic tannic acid (TA) can specifically target elastin and collagen, thereby enhancing the treatment of heart disease; the replacement of cholesterol with triterpenoid ginsenoside Rg in the lipid bilayer of liposomes can target GLUT1 receptors, thereby improving cancer treatment. Compared with other natural small molecule compounds such as flavonoids, terpenes, phenols and steroids, although alkaloids are one of the earliest natural products studied to date and have made exciting discoveries, their discovery and application as auxiliary materials for drug delivery strategies are still in their infancy.
[0003] Berberine is the most widely distributed alkaloid in the isoquinoline series. Its analogs such as jatrorrhizine, tertium pine and palmatine are all protoberberines naturally present in various plants. Tetrahydroberberine can be extracted from plants or obtained by hydrogenation of berberine. Compared with berberine itself, tetrahydroberberine has higher bioavailability and potential therapeutic effects, so it has attracted much attention. These protoberberines with isoquinoline or tetrahydroisoquinoline as the skeleton have multiple pharmacological properties such as antibacterial, anti-inflammatory, antioxidant, anti-diabetic, hypolipidemic and anti-tumor, so they have become a hot spot in traditional and modern medical research, but they are basically developed and applied from the perspective of drugs or lead compounds. Based on the structural properties of berberines characterized by tertiary amines and quaternary amines, it is predicted that they may produce electrostatic interactions with nucleic acid drugs and have the potential to be used as nucleic acid delivery carriers.
[0004] At present, the mainstream material for nucleic acid delivery is ionizable lipids, most of which use simple linear tertiary amine structures to achieve pH sensitivity. Due to the influence of steric hindrance, ionizable lipid designs rarely use cyclic tertiary amine head groups. Although berberine has a tertiary amine structure, the steric hindrance effect brought by its polycyclic ring may limit its ionization properties, so whether berberine can be developed into a carrier material for delivering nucleic acid drugs remains to be investigated. In addition, studies have shown that berberine has unique biomembrane permeability, such as directly acting on the biofilm of Candida albicans, or being specifically distributed in the subcellular structure mitochondria, so whether it can be used to overcome physiological barriers still needs further exploration. Summary of the invention
[0005] In view of this, one of the objects of the present invention is to provide berberine derivatives; the second object of the present invention is to provide a method for preparing berberine derivatives; the third object of the present invention is to provide berberine derivatives and their use in brain-targeted drug delivery.
[0006] In order to achieve the above object, the present invention provides the following technical solutions:
[0007] 1. A berberine derivative, wherein the structural formula of the berberine derivative is AB, wherein B is -C a H 2a-2m-1 、-COC a H 2a-2m-2 , C b H 2b+1 OCO(CH 2 ) y -, XC a H 2a CO-、-C a H 2a+1 OC c H 2c+1 Ph, -C a H 2a+1 NHCOC b H 2b-1 , -C a H 2a+ 1 COOH, -COC a H 2a NHC b H 2b+1 OCOC c H 2c+1 、-COC a H 2a+1 NHC c H 2c-2m-1 、-COC a H 2a+1 (NH 2 )C c H 2c+1 NHC d H 2d+1 (OH)C e H 2e+1 、-COC a H 2a+1 (NH 2 )C c H 2c+1 N(C d H 2d+1 (OH)C e H 2e+1 ) 2 、-COC a H 2a+1 N(Cb H 2b+1 OCOC c H 2c+1 ) 2 、-COC a H 2a+1 N(C c H 2c-2m-1 ) 2 or any one of DSPE-PEG-,
[0008] wherein a is an integer of 10 to 18, b is an integer of 10 to 18, c is an integer of 10 to 18, d is an integer of 10 to 18, e is an integer of 10 to 18, Ph is a benzene ring, X is a halogen, and m is the number of carbon-carbon double bonds;
[0009] The structural formula of A is any one of A1 to A5:
[0010]
[0011] Preferably, any one of the structural formulas B1 to B16 of B is:
[0012]
[0013]
[0014] Preferably, the berberine derivative includes any one of Compound 1 to Compound 21:
[0015]
[0016]
[0017] 2. A method for preparing the above berberine derivative, the method comprising the following steps:
[0018] When the structural formula of A is A1 or A2, and B is -C a H 2a-2b-1 When, the preparation method is as described in the following method 1: AH and BX are dissolved in N,N-dimethylformamide (DMF), potassium carbonate and potassium iodide are added, and the mixture is stirred at room temperature for 12 to 36 hours under a nitrogen atmosphere, and the reaction is monitored by thin layer chromatography. After the reaction is completed, the mixture is filtered and concentrated under vacuum, and purified by column chromatography;
[0019] When the structural formula of A is A1 or A2, and B is XC a H 2a CO-、-COC a H 2a+1 (NH 2 )C c H 2c+1N(C d H 2d+1 (OH)C e H 2e+1 ) 2 or -COC a H 2a+1 N(C c H 2c-2b-1 ) 2 The preparation method is as described in the second method below: B-OH is dissolved in dry dichloromethane, N,N-dicyclohexylcarbodiimide (DCC) and methylaminopyridine toluenesulfonate (DPTS) are added, and the mixture is stirred at room temperature under a nitrogen atmosphere for 0.5 to 1 hour to obtain a reaction mixture, AH is dissolved in N,N-dimethylformamide (DMF) and then added dropwise to the reaction mixture, and the mixture is reacted at room temperature under a nitrogen atmosphere for 24 to 48 hours, and the reaction is monitored by thin layer chromatography. After the reaction is completed, the mixture is filtered and concentrated under vacuum, and purified by column chromatography;
[0020] When the structural formula of A is A3 and B is -C a H 2a-2b-1 or -C a H 2a+1 OC c H 2c+1 When Ph, the preparation method is as described in the following method 3: 2,3-dihydroxytetrahydroberberine and BX are dissolved in N,N-dimethylformamide (DMF) to form a reaction mixture, potassium carbonate and potassium iodide are added, and the mixture is stirred at room temperature under a nitrogen atmosphere for 12 to 36 hours, and the reaction is monitored by thin layer chromatography. After the reaction is completed, the mixture is filtered and concentrated under vacuum, and purified by column chromatography;
[0021] When the structural formula of A is A3 and B is -COC a H 2a-2m-2 , -C a H 2a+1 NHCOC b H 2b-1 、-COC a H 2a+1 NHC c H 2c-2m-1 or -COC a H 2a+1 (NH 2 )C c H 2c+1 NHC d H 2d+1 (OH)C e H 2e+1, the preparation method is as described in method 4 below: dissolving B-OH in dry dichloromethane, adding N,N-dicyclohexylcarbodiimide (DCC) and dimethylaminopyridine toluenesulfonate (DPTS), stirring and reacting at room temperature for 30 minutes under a nitrogen atmosphere to obtain a reaction mixture, dissolving 2,3-dihydroxytetrahydroberberine in N,N-dimethylformamide (DMF) and then adding dropwise to the reaction mixture, stirring and reacting at room temperature for 24 to 48 hours under a nitrogen atmosphere, monitoring the reaction by thin layer chromatography, filtering and concentrating under vacuum after the reaction is completed, and purifying by column chromatography;
[0022] When the structural formula of A is A4 and B is -C a H 2a+1 COOH, the preparation method is as described in the following method 5: 9-hydroxytetrahydropalmatine and XC a H 2a+1 COOH is dissolved in N,N-dimethylformamide (DMF), potassium carbonate and potassium iodide are added, and the mixture is stirred for 12 to 36 hours under nitrogen atmosphere at room temperature. The reaction is monitored by thin layer chromatography. After the reaction is completed, the mixture is filtered and concentrated under vacuum, and then purified by column chromatography.
[0023] When the structural formula of A is A4 or A5, and B is -COC a H 2a NHC b H 2b+1 OCOC c H 2c+1 、-COC a H 2a+1 -NH 2 -C c H 2c+1 N(C d H 2d+1 (OH)C e H 2e+1 ) 2 、-COC a H 2a+1 N(C b H 2b+1 OCOC c H 2c+1 ) 2 or -COC a H 2a+1 N(C c H 2c-2m-1 ) 2When, the preparation method is as described in the following method 6: B-OH is dissolved in dry dichloromethane, N, N-dicyclohexylcarbodiimide (DCC) and dimethylaminopyridine toluenesulfonate (DPTS) are added, and the mixture is stirred for 0.5 to 1 h under a nitrogen atmosphere at room temperature, 9-hydroxytetrahydropalmatine or 9-hydroxytetrahydroberberine is dissolved in N, N-dimethylformamide (DMF) and then added dropwise to the reaction mixture, and the mixture is stirred at room temperature and under a nitrogen atmosphere for 24 to 48 h, and the reaction is monitored by thin layer chromatography. After the reaction is completed, the mixture is filtered and concentrated under vacuum, and purified by column chromatography;
[0024] When the structural formula of A is A2 and B is DSPE-PEG-, the preparation method is as described in the following method 7: COOH-PEG-DSPE, tetrahydroafricanine, and benzotriazol-1-yl-oxytripyrrolidinophosphine hexafluorophosphate (PyBop) are dissolved in N,N-dimethylformamide, stirred at room temperature for 24 to 48 hours, placed in a dialysis bag after the reaction is completed, dialyzed with pure water for 24 to 48 hours, taken out, and freeze-dried;
[0025] wherein a is an integer of 10 to 18, b is an integer of 10 to 18, c is an integer of 10 to 18, d is an integer of 10 to 18, e is an integer of 10 to 18, Ph is a benzene ring, X is a halogen, m is the number of carbon-carbon double bonds, DSPE-PEG- is
[0026] Preferably, the eluent used in the column chromatography purification is a mixed solution consisting of methanol and dichloromethane in a volume ratio of 10:90 to 90:10.
[0027] Preferably, in method 1, the molar ratio of AH, BX, potassium carbonate and potassium iodide is 0.1:0.35:0.3:0.01;
[0028] In method 2, the molar ratio of AH, B-OH, N,N-dicyclohexylcarbodiimide (DCC) and methylaminopyridine toluenesulfonate (DPTS) is 0.1:0.35:0.6:0.06;
[0029] In method 3, the molar ratio of A3-H (2,3-dihydroxytetrahydroberberine), BX, potassium carbonate and potassium iodide is 0.1:0.35:0.3:0.01;
[0030] In method 4, the molar ratio of A3-H (2,3-dihydroxytetrahydroberberine), BX, potassium carbonate and potassium iodide is 0.1:0.4:0.6:0.6;
[0031] In method 5, the 9-hydroxytetrahydropalmatine, XC a H 2a+1The molar ratio of COOH, potassium carbonate and potassium iodide is 0.1:0.35:0.3:0.01;
[0032] In method six, the molar ratio of A4-H (9-hydroxytetrahydropalmatine) or A5-H (9-hydroxytetrahydroberberine), B-OH, N,N-dicyclohexylcarbodiimide (DCC) and dimethylaminopyridine toluenesulfonate (DPTS)) is 0.1:0.4:0.6:0.6;
[0033] In method seven, the molar ratio of tetrahydroafricanine, COOH-PEG-DSPE and benzotriazol-1-yl-oxytripyrrolidinophosphine hexafluorophosphate (PyBop) is 2:1:3.
[0034] Preferably, in method three, the 2,3-dihydroxytetrahydroberberine is prepared according to the following method: dissolving tetrahydroberberine in dry dichloromethane at 0°C, stirring and dissolving under a nitrogen atmosphere, adding a n-hexane solution containing boron trichloride, stirring at 0°C for 0.5 to 1h, and then stirring at room temperature for 4 to 6h, and the reaction is quenched with miliQ water for 0.5 to 2h; concentrating under vacuum, and purifying by column chromatography to obtain 2,3-dihydroxytetrahydroberberine.
[0035] Preferably, in method five, the 9-hydroxytetrahydrobamipine is prepared as follows: tetrahydrobamipine is placed in a thermal decomposition reactor and reacted at 180-200° C. for 1-4 h to obtain 9-hydroxytetrahydrobamipine.
[0036] 3. Application of the above berberine derivatives in brain-targeted drug delivery.
[0037] 4. Use of the above berberine derivatives in nucleic acid delivery.
[0038] The beneficial effects of the present invention are as follows: the present invention discloses a berberine derivative and a preparation method and application thereof, wherein the structural formula of the berberine derivative is AB, wherein A is a group formed by berberine and its derivatives having two tetrahydroisoquinoline fusion structural skeletons losing methyl or hydrogen atoms, B is a straight-chain alkenyl group having 10 to 18 carbon atoms, a straight-chain alkyl group having 10 to 18 carbon atoms substituted by a hydroxyl group, and the chemical formula is C x H 2x+1 OCO(CH 2 ) y-group or any one of DSPE-PEG-, wherein x and y are positive integers. Therefore, the berberine derivatives disclosed in the present invention belong to ionizable lipids mainly because they have two tetrahydroisoquinoline ring fusion skeletons. After comprehensive verification from molecular research to animal experiments, it was found that the berberine derivatives disclosed in the present invention show the following advantages: (i) It has a strong nucleic acid carrying capacity and can improve the stability of nucleic acids by forming a self-structure; (ii) It is particularly conducive to the escape of nucleic acid drugs from lysosomes and improves intracellular transport; (iii) In vitro, it exhibits super brain targeting properties in a specific manner, and also shows the same trend in vivo (mainly due to active targeting mediated by dopamine receptors). Therefore, the berberine derivatives disclosed in the present invention can be used as an ionizable lipid for constructing a safe and efficient nucleic acid drug or brain-targeted delivery system.
[0039] Other advantages, objectives and features of the present invention will be described in the following description to some extent, and to some extent, will be obvious to those skilled in the art based on the following examination and study, or can be taught from the practice of the present invention. The objectives and other advantages of the present invention can be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be described in detail below in conjunction with the accompanying drawings, wherein:
[0041] Figure 1 It is a transmission electron microscopy scanning image of lipid nanoparticles (LNP) formed by compound 6;
[0042] Figure 2 is the pKa value of different berberine derivatives;
[0043] Figure 3 is the fluorescence intensity of different berberine derivatives (A1-B15, A2-B13, A3-B1, A4-B15) at an excitation wavelength of 305 nm;
[0044] Figure 4 Fluorescence intensity of lipid nanoparticles formed by different berberine derivatives (A1-B4, A1-B15, A2-B5, A2-B13, A3-B1, A3-B7, A4-B15, A5-B13) and Lipo2000 loaded with eGFP mRNA;
[0045] Figure 5 The cytotoxicity test results of lipid nanoparticles formed by different berberine derivatives (A1-B13, A1-B15, A2-B13, A2-B15, A3-B1, A3-B3, A4-B14, A4-B15, A5-B13, A5-B14);
[0046] Figure 6 N / P ratio of lipid nanoparticles formed by berberine derivatives (A2-B13) after encapsulating siRNA;
[0047] Figure 7 The endosomal escape effect of siRNA loaded with lipid nanoparticles formed by different berberine derivatives (A3-B1, A2-B13, A1-B15);
[0048] Figure 8 a is COOH-PEG 2000 a is the mass spectrum of DSPE, b is the mass spectrum of compound 21;
[0049] Fig. 9 The DiD fluorescence intensity of different berberine derivatives ((Compound 3 (A1-B15), Compound 6 (A2-B13), Compound 8 (A3-B1), Compound 18 (A4-B15), Compound 19 (A5-B13), Compound 21 (A2-B16)) and the common preparation (control group) under a fluorescence microscope in different dosing groups;
[0050] Fig.10 The uptake of berberine derivatives (A2-B13) and common preparations (control group) by bEnd.3 cells before and after dopamine receptor silencing;
[0051] Fig.11 Fluorescence images of different berberine derivatives (compound 3 (A1-B15), compound 6 (A2-B13), compound 8 (A3-B1), compound 18 (A4-B15), compound 19 (A5-B13)) and common preparation (control group) after loading DiR;
[0052] Fig.12 The fluorescence images of berberine derivatives (A2-B13) and their combinations with scutellaria baicalenol, gallic acid and citric acid, respectively. DETAILED DESCRIPTION
[0053] The following describes the embodiments of the present invention by specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that the illustrations provided in the following embodiments only illustrate the basic concept of the present invention in a schematic manner, and the following embodiments and features in the embodiments can be combined with each other without conflict.
[0054] In the following embodiments, the structural formula involved is as follows:
[0055] Structural formulas A1 to A5 are shown below:
[0056]
[0057] The structural formulas B1 to B16 are shown below:
[0058]
[0059]
[0060] The structural formulas of Compound 1 to Compound 21 are:
[0061]
[0062]
[0063] Compound 21
[0064] In addition, in the following embodiments, a is an integer of 10 to 18, b is an integer of 10 to 18, c is an integer of 10 to 18, d is an integer of 10 to 18, e is an integer of 10 to 18, Ph is a benzene ring, X is a halogen, and m is the number of carbon-carbon double bonds.
[0065] Example 1
[0066] A berberine derivative (Compound 1, A1-B4), the specific preparation method is as follows:
[0067] Tetrahydrojatrorrhizine (34 mg, 0.1 mmol) and ethyl 11-bromodencanoate (103 mg, 0.35 mmol) were dissolved in N,N-dimethylformamide (30 mL) to form a reaction mixture, potassium carbonate (42 mg, 0.3 mmol) and potassium iodide (2 mg, 0.01 mmol) were added, and the mixture was stirred for 16 h under a nitrogen atmosphere at room temperature. The reaction was monitored by thin layer chromatography. After the reaction was completed, the mixture was filtered and concentrated under vacuum, and purified by column chromatography (the eluent was a mixed solution of methanol and dichloromethane in a volume ratio of 10:90) to obtain compound 1.
[0068] Compound 1: 1 HNMR (400 MHz, DMSO-d 6)δ6.89(dt,J=7.3,0.9Hz,1H),6.82(d,J=7.5Hz,1H),6.76(d,J=0.7Hz,1H),6.60(t,J=1.0Hz,1H),4.17 –4.03(m,2H),4.03–3.91(m,2H),3.83–3.78(m,9H),3.72–3.57(m,3H),3.21(dt,J=12.3,7.1Hz,1H),3.1 3(dt,J=12.4,7.1Hz,1H),2.94(ddd,J=12.5,7.0,0.9Hz,1H),2.76–2.61(m,3H),2.34–2.25(m,2H),1.7 8(pd,J=7.1,0.9Hz,2H),1.63–1.35(m,4H),1.35–1.23(m,7H),1.27–1.22(m,1H),1.22(t,J=8.0Hz,4H).
[0069] Example 2
[0070] According to the reaction steps in Example 1 (i.e., replacing certain reactants in the example, the addition ratio and other reaction conditions are the same as those in Example 1), the following compounds were prepared:
[0071] Compound 4 (A2-B5): Compound 4 was prepared by replacing tetrahydrojatrorrhizine in Example 1 with tetrahydrotetrahydrochalcone and replacing 11-bromodecaneic acid ethyl ester in Example 1 with tert-butyl 11-bromodecaneic acid. 1 H NMR (400 MHz, DMSO-d 6 )δ6.89(dt,J=7.3,0.9Hz,1H),6.82(d,J=7.5Hz,1H),6.71(d,J=0.7Hz,1H),6.57(t,J=1.0Hz,1H) ,4.03–3.91(m,2H),3.85–3.78(m,8H),3.72–3.57(m,3H),3.21(dt,J=12.3,7.1Hz,1H),3.13(dt, J=12.4,7.1Hz,1H),2.94(ddd,J=12.5,7.0,0.9Hz,1H),2.76–2.61(m,3H),2.34(td,J=7.1,1.3Hz ,2H),1.78(p,J=7.1Hz,2H),1.54–1.34(m,4H),1.41(s,9H),1.34–1.22(m,7H),1.25–1.19(m,1H).
[0072] It can be seen from the above Examples 1 and 2 that according to the preparation method of Example 1, the reactants in the reaction, when AH is A1-H (tetrahydrojatrorrhizine) or A2-H (tetrahydroafricanine), BX is XC a H 2a-2b-1 When (X is halogen), a berberine derivative with a structural formula of AB can be obtained, wherein the structural formula of A is A1 or A2, and B is -C a H 2a-2b-1 .
[0073] Example 3
[0074] A berberine derivative (Compound 2, A1-B13), the specific preparation method is as follows:
[0075] (1) N6,N6-bis(2-hydroxydodecyl)lysine (180 mg, 0.35 mmol) was dissolved in dry dichloromethane (30 mL) and mixed evenly, N,N-dicyclohexylcarbodiimide (DCC, 124 mg, 0.6 mmol) and dimethylaminopyridine p-toluenesulfonate (DPTS, 177 mg, 0.6 mmol) were added, and stirred at room temperature under nitrogen atmosphere for 30 min to form a reaction mixture;
[0076] (2) Tetrahydrochalcone (34 mg, 0.1 mmol) was dissolved in N,N-dimethylformamide (DMF, 2 mL) and then added dropwise to the reaction mixture in step (1). The mixture was stirred for 24 h under nitrogen atmosphere at room temperature. The reaction was monitored by thin layer chromatography. After the reaction was completed, the mixture was filtered and concentrated under vacuum, and purified by column chromatography (the eluent was a mixed solution of methanol and dichloromethane in a volume ratio of 20:80) to obtain compound 2.
[0077] Compound 2: 1 H NMR (400 MHz, DMSO-d 6 )δ6.84–6.78(m,1H),3.85(s,1H),3.84–3.79(m,3H),3.77–3.71(m,1H),3.74–3.65(m,1H),3.68–3.57(m,1H),3.26–3.08(m,1H),2.98–
[0078] 2.86(m,1H),2.84–2.71(m,1H),2.73–2.62(m,1H),2.59–2.51(m,1H),1.81–1.67(m,1H),1.54–1.42(m,3H),1. 46–1.33(m,1H),1.36–1.29(m,1H),1.32–1.26(m,1H),1.29–1.21(m,7H),1.24–1.15(m,1H),0.93–0.84(m,2H).
[0079] Example 4
[0080] According to the reaction steps in Example 3 (i.e., replacing certain reactants in the example, the addition ratio and other reaction conditions are the same as those in Example 3), the following compounds were prepared:
[0081] (1) Compound 3 (A1-B15): 3-(di((6E,9E)-octadec-6,9-dien-1-yl)amino)butyric acid was used to replace N6,N6-bis(2-hydroxydodecyl)lysine in Example 3 to prepare Compound 3. 1 H NMR (400 MHz, DMSO-d 6 )δ6.92–6.86(m,1H),6.81(d,J=7.6Hz,1H),5.57–5.47(m,2H),5.37–5.27(m,2H),3.83(d,J=17.6Hz,4H),3.72– 3.57(m,1H),3.42(h,J=6.8Hz,0H),3.26–3.08(m,1H),2.94(ddd,J=12.5,7.0,0.9Hz,0H),2.76–2.62(m,3H),2. 62–2.50(m,2H),2.26–2.12(m,2H),1.90(dtdd,J=12.4,7.2,6.2,1.1Hz,1H),1.85–1.70(m,3H),1.62–1.49(m,1 H),1.49–1.33(m,4H),1.37–1.25(m,4H),1.29–1.20(m,6H),1.23–1.18(m,2H),1.18(s,1H),0.94–0.84(m,3H).
[0082] (2) Compound 5 (A2-B6): Compound 5 was prepared by replacing tetrahydrojatrorrhizine in Example 3 with tetrahydrotetracycline and replacing N6,N6-bis(2-hydroxydodecyl)lysine in Example 3 with 9-bromononanoic acid. 1 H NMR (400 MHz, DMSO-d 6)δ7.03(d,J=0.6Hz,1H),6.89(dt,J=7.5,1.0Hz,1H),6.82(d,J=7.5Hz,1H),6.62(t,J=1.0Hz,1H),3.81(d,J=6.5Hz,8H),3.72–3.64 (m,2H),3.60(d,J=12.5Hz,1H),3.49(dt,J=12.3,7.1Hz,1H),3.37(dt,J=12.4,7.1Hz,1H),3.21(dt,J=12.4,7.1Hz,1H),3.13(dt,J=
[0083] 12.5,7.0Hz,1H),2.94(ddd,J=12.4,7.0,0.9Hz,1H),2.76–2.61(m,3H),2.49(td,J=7.1,1.9Hz,2H ),1.93(dp,J=12.3,7.0Hz,1H),1.76(dp,J=12.3,7.1Hz,1H),1.69–1.51(m,3H),1.46–1.21(m,7H).
[0084] (3) Compound 6 (A2-B13): Compound 6 was prepared by replacing tetrahydrojatrorrhizine in Example 3 with tetrahydrotetrahydrochafrine. 1 H NMR (400 MHz, DMSO-d 6 )δ3.85(s,1H),3.82(s,2H),3.81(d,J=9.0Hz,1H),3.78–3.71(m,1H),3.74–3.66(m,1H),3.69–3.57(m,1H),3.26– 3.08(m,1H),2.98–2.86(m,1H),2.84–2.61(m,2H),2.59–2.51(m,1H),1.81–1.67(m,1H),1.54–1.46(m,1H),1.50–
[0085] 1.41(m,2H),1.44–1.32(m,1H),1.35–1.28(m,1H),1.31–1.24(m,3H),1.28–1.15(m,6H),0.94–0.84(m,2H).
[0086] (4) Compound 7 (A2-B15): Compound 7 was prepared by replacing tetrahydrojatrorrhizine in Example 3 with tetrahydrotetracycline and replacing N6,N6-bis(2-hydroxydodecyl)lysine in Example 3 with 3-(di((6E,9E)-octadec-6,9-dien-1-yl)amino)butyric acid. 1H NMR (400 MHz, DMSO-d 6 )δ7.01(d,J=0.6Hz,1H),6.89(dt,J=7.3,0.9Hz,1H),6.81(d,J=7.5Hz,1H),6 .62(t,J=1.0Hz,1H),5.57–5.47(m,4H),5.37–5.27(m,4H),3.83(d,J=17.6Hz, 8H),3.72–3.65(m,2H),3.60(d,J=12.3Hz,1H),3.42(h,J=6.8Hz,1H),3.21(d t,J=12.5,7.1Hz,1H),3.13(dt,J=12.4,7.0Hz,1H),2.94(ddd,J=12.4,7.0,0. 9Hz,1H),2.76–2.66(m,2H),2.69–2.62(m,3H),2.62–2.50(m,4H),2.26–2.12 (m,4H),1.90(dtdd,J=12.4,7.2,6.2,1.1Hz,2H),1.85–1.70(m,6H),1.62–1.4 9(m,2H),1.49–1.33(m,9H),1.33(ddd,J=5.4,3.2,1.7Hz,1H),1.33–1.24(m,1 2H),1.27–1.20(m,7H),1.20(d,J=3.3Hz,3H),1.18(s,2H),0.95–0.84(m,6H).
[0087] It can be seen from the above Examples 3 and 4 that according to the preparation method of Example 3, the reactant AH in the reaction is A1-H (tetrahydrojatrorrhizine) or A2-H (tetrahydroafricanine), B-OH is XC a H 2a COOH、HOCOC a H 2a+1 (NH 2 )C c H 2c+ 1 N(C d H 2d+1 (OH)C e H 2e+1 ) 2 or HOCOC a H 2a+1 N(C c H 2c-2b-1 ) 2 When (X is halogen), a berberine derivative with a structural formula of AB can be obtained, wherein the structural formula of A is A1 or A2, and B is XC a H2a CO-、-COC a H 2a+1 (NH 2 )C c H 2c+1 N(C d H 2d+1 (OH)C e H 2e+1 ) 2 or -COC a H 2a+1 N(C c H 2c-2b-1 ) 2 .
[0088] Example 5
[0089] A berberine derivative (Compound 8, A3-B1), the specific preparation method is as follows:
[0090] (1) Tetrahydroberberine (50 mg, 0.15 mmol) was dissolved in dry dichloromethane (30 mL) at 0°C and stirred for 10 min under a nitrogen atmosphere; then a n-hexane solution of boron trichloride (1 M, 1 mL, 1 mmol) was added to the mixture, stirred at 0°C for 30 min and then at room temperature for 4 h, and the reaction was quenched with miliQ water (2 mL) for 30 min; concentrated under vacuum and purified by column chromatography to obtain 2,3-dihydroxytetrahydroberberine.
[0091] (2) 2,3-Dihydroxytetrahydroberberine (31 mg, 0.1 mmol) and (6E,9E)-17-bromoheptadec-6,9-diene (111 mg, 0.35 mmol) were dissolved in N,N-dimethylformamide (30 mL) to form a reaction mixture, potassium carbonate (42 mg, 0.3 mmol) and potassium iodide (2 mg, 0.01 mmol) were added, and the mixture was stirred for 16 h under nitrogen atmosphere at room temperature. The reaction was monitored by thin layer chromatography. After the reaction was completed, the mixture was filtered and concentrated under vacuum, and purified by column chromatography (the eluent was a mixed solution of methanol and dichloromethane, the initial volume ratio of methanol to dichloromethane was 10:90, and then the proportion of methanol was increased, and finally the volume ratio of methanol to dichloromethane was 90:10) to obtain compound 8.
[0092] Compound 8: 1 H NMR (400 MHz, DMSO-d 6)δ7.00(d,J=0.7Hz,1H),6.94–6.86(m,2H),6.81(d,J=7.5Hz,1H),5.46 (dddt,J=15.1,6.2,5.2,1.1Hz,2H),5.39–5.13(m,11H),3.84(d,J=17.4 Hz,5H),3.72–3.65(m,2H),3.60(d,J=12.3Hz,1H),3.21(dt,J=12.5,7.2Hz,1H),3.13(dt,J=12.4,7.0Hz,1H),2.94(ddd,J=12.4,7.0,0.9Hz,1H ),2.76–2.69(m,1H),2.72–2.62(m,2H),2.49(td,J=7.0,0.8Hz,4H),2. 26–1.82(m,13H),1.86–1.76(m,1H),1.80–1.73(m,1H),1.68(dtdd,J=12 .4,7.1,6.1,0.9Hz,1H),1.55(p,J=7.1Hz,4H),1.31(dd,J=7.0,1.0Hz, 1H), 1.31–1.23 (m, 4H), 1.27–1.15 (m, 10H), 0.95 (td, J = 8.0, 1.0Hz, 6H).
[0093] Example 6
[0094] According to the reaction steps in Example 5 (i.e., replacing certain reactants in the example, the addition ratio and other reaction conditions are the same as those in Example 5), the following compounds were prepared:
[0095] Compound 11 (A3-B7): 5-(benzyloxy)pentyl hypobromous acid was used to replace (6E,9E)-17-bromoheptadec-6,9-diene in Example 5 to prepare Compound 11, which 1 H NMR (400 MHz, DMSO-d 6)δ7.37–7.25(m,11H),6.89(dt,J=7.5,1.0Hz,1H),6.83(d,J=7.5Hz,1H),6.72(d,J=0.6Hz,1H),6.60(d,J=1.1H z,1H),4.42(q,J=0.9Hz,4H),3.98(td,J=7.0,4.0Hz,4H),3.85(s,2H),3.81(s,2H),3.72–3.57(m,3H),3.53–3. 38(m,4H),3.21(dt,J=12.3,7.1Hz,1H),3.13(dt,J=12.4,7.1Hz,1H),2.94(ddd,J=12.5,7.0,0.9Hz,1H),2.76– 2.61(m,3H),1.72(p,J=7.0Hz,4H),1.69–1.58(m,4H),1.61–1.55(m,1H),1.58–1.49(m,2H),1.52–1.42(m,1H).
[0096] It can be seen from the above Examples 5 and 6 that according to the preparation method of Example 5, in the reaction, AH is A3-H (2,3-opened tetrahydroberberine), BX is XC a H 2a-2b-1 or XC a H 2a+1 OC c H 2c+1 Ph (X is halogen), a berberine derivative with the structural formula AB can be obtained, wherein the structural formula of A is A3, B is -C a H 2a-2b-1 or -C a H 2a+1 OC c H 2c+1 Ph.
[0097] Example 7
[0098] A berberine derivative (Compound 9, A3-B2) was prepared. The specific preparation method is as follows:
[0099] (1) Tetrahydroberberine (50 mg, 0.15 mmol) was dissolved in dry dichloromethane (30 mL) at 0°C and stirred for 10 min under a nitrogen atmosphere. Then, a n-hexane solution of boron trichloride (1 M, 1 mL, 1 mmol) was added, and the mixture was stirred at 0°C for 30 min and then at room temperature for 4 h. The reaction was quenched with miliQ water (2 mL) for 30 min. The product was concentrated under vacuum and purified by column chromatography to obtain 2,3-dihydroxytetrahydroberberine.
[0100] (2) (9E,12E)-heptadeca-9,12-dienoic acid (107 mg, 0.4 mmol) was dissolved in dry dichloromethane (30 mL) to form a reaction mixture, and N,N-dicyclohexylcarbodiimide (DCC, 124 mg, 0.6 mmol) and dimethylaminopyridine toluenesulfonate (DPTS, 177 mg, 0.6 mmol) were added to the reaction mixture, and the mixture was stirred for 30 min at room temperature under a nitrogen atmosphere. 2,3-Dihydroxytetrahydroberberine (31 mg, 0.1 mmol) was dissolved in N,N-dimethylformamide (DMF, 2 mL) and then added dropwise to the reaction mixture, and the mixture was stirred for 24 h at room temperature under a nitrogen atmosphere. The reaction was monitored by thin layer chromatography. After the reaction was completed, the mixture was filtered and concentrated under vacuum, and purified by column chromatography (the eluent was a mixed solution of methanol and dichloromethane in a volume ratio of 10:90) to obtain compound 9.
[0101] Compound 9: 1 HNMR (400 MHz, DMSO-d 6 )δ6.94–6.86(m,1H),5.52(dtt,J=15.5,6.2,1.1Hz,2H),5.37–5.27(m,2H),3.84(d,J=17.4Hz,2H), 3.72–3.65(m,1H),3.26–3.08(m,1H),2.94(ddd,J=12.4,7.0,0.9Hz,0H),2.76–2.62(m,2H),2.49(t d,J=7.0,0.8Hz,2H),2.25–2.12(m,2H),1.97–1.73(m,3H),1.68(ddtd,J=14.2,7.1,6.1,0.9Hz,0H) ,1.55(p,J=7.1Hz,2H),1.38–1.30(m,2H),1.33–1.23(m,6H),1.27–1.15(m,5H),0.95–0.83(m,3H).
[0102] Example 8
[0103] According to the reaction steps in Example 7 (i.e., replacing certain reactants in the example, the addition ratio and other reaction conditions are the same as those in Example 7), the following compounds were prepared:
[0104] (1) Compound 10 (A3-B3): (9E,12E,15E)-heptadeca-9,12,15-trienoic acid was used to replace (9E,12E)-heptadeca-9,12-dienoic acid in Example 7 to prepare Compound 10, which 1 HNMR (400 MHz, DMSO-d 6)δ5.52(dtt,J=14.6,6.2,1.1Hz,1H),5.37–5.27(m,1H),3.97(tt,J=7.1,2 .5Hz,1H),3.84(d,J=17.4Hz,1H),3.72–3.57(m,1H),3.26–3.08(m,1H),2. 76–2.61(m,1H),2.24–2.13(m,1H),1.95–1.83(m,1H),1.86–1.63(m,2H),1 .47–1.39(m,1H),1.42–1.30(m,1H),1.33–1.19(m,5H),0.95–0.83(m,2H).
[0105] (2) Compound 12 (A3-B8): Compound 12 was prepared by replacing the (9E,12E)-heptadeca-9,12-dienoic acid in Example 7 with 6-acrylamidohexanoic acid. 1 H NMR (400 MHz, DMSO-d 6 )δ7.03(s,1H),6.94–6.86(m,2H),6.83(d,J=7.5Hz,1H),6.74(t,J=6.8Hz,2H),6.40–6.31(m,2H),5.89(d dd,J=12.1,3.1,1.7Hz,2H),5.83(ddd,J=15.0,3.1,1.7Hz,2H),3.85(s,2H),3.81(s,2H),3.72–3.64(m,2 H),3.60(d,J=12.3Hz,1H),3.26–3.07(m,6H),3.01(ddd,J=12.4,6.9,1.0Hz,1H),2.90(ddd,J=12.5,7.0, 0.9Hz,1H),2.83–2.77(m,2H),2.53–2.44(m,4H),1.60–1.44(m,9H),1.47–1.38(m,3H),1.42–1.34(m,1H).
[0106] (3) Compound 13 (A3-B11): Compound 13 was prepared by replacing the (9E,12E)-heptadeca-9,12-dienoic acid in Example 7 with 3-(((6E,9E)-octadec-6,9-dien-1-yl)amino)butyric acid. 1 H NMR (400 MHz, DMSO-d 6)δ6.94–6.86(m,1H),5.52(dtt,J=15.6,6.3,1.1Hz,2H),5.37–5.27(m,2H) ,3.84(d,J=17.4Hz,2H),3.72–3.65(m,1H),3.63–3.53(m,1H),3.44(dt,J= 8.1,6.4Hz,1H),3.26–2.91(m,3H),2.76–2.63(m,1H),2.63–2.50(m,2H),2 .25–2.12(m,2H),1.95–1.70(m,4H),1.57–1.14(m,18H),0.94–0.84(m,3H).
[0107] (4) Compound 14 (A3-B12): Compound 14 was prepared by replacing the (9E,12E)-heptadeca-9,12-dienoic acid in Example 7 with N6-(2-hydroxydodecyl)lysine. 1 H NMR (400 MHz, DMSO-d 6 )δ6.93–6.86(m,1H),4.11(tt,J=7.7,6.3Hz,1H),3.95(d,J=9.0Hz,2H),3.88–3.83(m,2H),3. 82(s,1H),3.72–3.57(m,3H),3.17(ddt,J=43.1,12.4,7.1Hz,1H),2.98–2.89(m,1H),2.89–2.8 0(m,1H),2.76–2.63(m,3H),1.81–1.67(m,2H),1.54–1.43(m,2H),1.46–1.38(m,3H),1.42–1.3 2(m,1H),1.36–1.27(m,2H),1.27(dp,J=6.6,2.3Hz,4H),1.27–1.16(m,7H),0.93–0.84(m,3H).
[0108] It can be seen from the above Examples 7 and 8 that according to the preparation method of Example 7, AH in the reaction is A3-H (2,3-dihydroxytetrahydroberberine), B-OH is HOCOC a H 2a-2m-2 、HOC a H 2a+1 NHCOC b H 2b-1 、HOCOC a H 2a+ 1 NHC c H 2c-2m-1 or HOCOC a H2a+1 (NH 2 )C c H 2c+1 NHC d H 2d+1 (OH)C e H 2e+1 ), a berberine derivative with a structural formula of AB can be obtained, wherein the structural formula of A is A3, and B is -COC a H 2a-2m-2 , -C a H 2a+1 NHCOC b H 2b-1 、-COC a H 2a+1 NHC c H 2c-2m-1 or -COC a H 2a+1 (NH 2 )C c H 2c+1 NHC d H 2d+1 (OH)C e H 2e+1 .
[0109] Example 9
[0110] A berberine derivative (Compound 15, A4-B9) was prepared. The specific preparation method is as follows:
[0111] (3) Tetrahydrobamipine (33 mg, 0.1 mmol) was placed in a thermal decomposition reactor and reacted at 190° C. for 2 h to obtain 9-hydroxytetrahydrobamipine.
[0112] (4) 9-Hydroxytetrahydropalmatine and 8-bromooctanoic acid (78 mg, 0.35 mmol) were dissolved in N,N-dimethylformamide (30 mL) to form a reaction mixture, potassium carbonate (42 mg, 0.3 mmol) and potassium iodide (2 mg, 0.01 mmol) were added, and the mixture was stirred for 16 h under nitrogen atmosphere at room temperature. The reaction was monitored by thin layer chromatography. After the reaction was completed, the mixture was filtered and concentrated under vacuum, and purified by column chromatography (the eluent was a mixed solution of methanol and dichloromethane, and the initial volume ratio of methanol to dichloromethane was 10:90, and then the proportion of methanol was increased, and finally the volume ratio of methanol to dichloromethane was 90:10) to obtain compound 15.
[0113] Compound 15: 1 H NMR (400 MHz, DMSO-d 6)δ6.89(dt,J=7.5,1.1Hz,1H),6.82(d,J=7.5Hz,1H),6.76(s,1H),6.57(t,J=1.0Hz,1H),4 .05–3.92(m,2H),3.84(d,J=4.1Hz,8H),3.72(d,J=12.4Hz,1H),3.67–3.61(m,2H),3.21(dt ,J=12.3,7.1Hz,1H),3.13(dt,J=12.5,7.1Hz,1H),2.94(ddd,J=12.3,7.0,0.9Hz,1H),2.7 6–2.61(m,3H),2.38–2.25(m,2H),1.88–1.77(m,2H),1.66–1.36(m,4H),1.36–1.24(m,4H).
[0114] It can be seen from the above Example 9 that according to the reaction method of Example 9, the reactant AH in the reaction is A4-H (9-hydroxytetrahydropalmatine), BX is XC a H 2a+1 COOH (X is halogen), a berberine derivative with the structural formula AB can be obtained, wherein the structural formula of A is A4, B is -C a H 2a+1 COOH.
[0115] Example 10
[0116] A berberine derivative (Compound 16, A4-B10) was prepared. The specific preparation method is as follows:
[0117] (1) Tetrahydrobamipine (33 mg, 0.1 mmol) was placed in a thermal decomposition reactor and reacted at 190° C. for 2 h to obtain 9-hydroxytetrahydrobamipine.
[0118] (2) 3-((9-(octyloxy)-9-oxononyl)amino)butyric acid (149 mg, 0.4 mmol) was dissolved in dry dichloromethane (30 mL) to form a reaction mixture, N,N-dicyclohexylcarbodiimide (DCC, 124 mg, 0.6 mmol) and dimethylaminopyridine p-toluenesulfonate (DPTS, 177 mg, 0.6 mmol) were added, and the mixture was stirred for 30 min at room temperature under nitrogen atmosphere; 9-hydroxytetrahydropalmatine was dissolved in N,N-dicyclohexylcarbodiimide (DCC, 124 mg, 0.6 mmol) and dimethylaminopyridine p-toluenesulfonate (DPTS, 177 mg, 0.6 mmol) were added to the reaction mixture. N-dimethylformamide (DMF, 2 mL) was then added dropwise to the reaction mixture, and the reaction was stirred at room temperature under nitrogen atmosphere for 24 h. The reaction was monitored by thin layer chromatography. After the reaction was completed, it was filtered and concentrated under vacuum, and purified by column chromatography (the eluent was a mixed solution of methanol and dichloromethane, with an initial volume ratio of methanol to dichloromethane of 10:90, and then the proportion of methanol was increased, and finally the volume ratio of methanol to dichloromethane was 90:10) to obtain compound 16.
[0119] Compound 16: 1 H NMR (400 MHz, DMSO-d 6 )δ6.99(dt,J=7.5,0.9Hz,1H),6.93(d,J=7.5Hz,1H),6.75(s,1H),6.57(t,J=0.9Hz,1H),4.14–3.99(m,2H),3.85–3.79(m,9H) ,3.82–3.70(m,2H),3.64(t,J=7.0Hz,1H),3.57(dq,J=8.1,6.9Hz,1H),3.45(dt,J=8.1,6.2Hz,1H),3.21(dt,J=12.5,7.1Hz,1 H),3.18–3.08(m,2H),3.02–2.95(m,1H),2.98–2.92(m,1H),2.79–2.66(m,2H),2.69–2.61(m,1H),2.61–2.51(m,2H),2.30(td ,J=7.1,2.3Hz,2H),1.64–1.44(m,6H),1.47–1.38(m,1H),1.41–1.30(m,4H),1.33–1.17(m,13H),1.16(d,J=6.8Hz,3H),0.94–
[0120] 0.84 (m, 3H).
[0121] Embodiment 11
[0122] According to the reaction steps in Example 10 (i.e., replacing certain reactants in the example, the addition ratio and other reaction conditions are the same as those in Example 10), the following compounds were prepared:
[0123] (1) Compound 17 (A4-B14): 3-(bis(9-(octyloxy)-9-oxononyl)amino)butyric acid was used to replace the 3-((9-(octyloxy)-9-oxononyl)amino)butyric acid in Example 10 to obtain Compound 17, which 1 H NMR (400 MHz, DMSO-d 6 )δ4.14–3.99(m,1H),3.85–3.78(m,2H),3.26–3.08(m,0H),2.79–2.64(m,1H),2.56(td ,J=7.0,2.1Hz,1H),2.30(td,J=7.1,1.8Hz,1H),1.64–1.15(m,12H),0.94–0.84(m,2H).
[0124] (2) Compound 18 (A4-B15): 3-(bis((6E,9E)-octadec-6,9-dien-1-yl)amino)butyric acid was used to replace the 3-(bis(9-(octyloxy)-9-oxononyl)amino)butyric acid in Example 10 to obtain Compound 18, which 1 H NMR (400 MHz, DMSO-d 6 )δ5.57–5.47(m,2H),5.37–5.27(m,2H),3.85–3.70(m,4H),3.26–3.08(m,1H),2.79–2.62(m,2H),2.62–2.50(m,2H),2.26–2.12(m ,2H),1.90(dtdd,J=12.4,7.2,6.2,1.1Hz,1H),1.85–1.70(m,2H),1.62–1.49(m,1H),1.49–1.31(m,4H),1.34–1.28(m,1H),1.31–
[0125] 1.25(m,2H),1.28–1.22(m,4H),1.25–1.14(m,3H),0.94–0.84(m,2H).
[0126] (3) Compound 19 (A5-B13): Tetrahydroberberine was used to replace tetrahydropalmatine in Example 10, and N6,N6-bis(2-hydroxydodecyl)lysine was used to replace 3-(bis(9-(octyloxy)-9-oxononyl)amino)butyric acid in Example 10 to obtain Compound 19, which 1 H NMR (400 MHz, DMSO-d 6)δ6.96(dt,J=7.4,1.0Hz,1H),6.90(d,J=7.5Hz,1H),6.72(s,1H),6.57(t,J=1.0Hz,1H),5.97(d,J=3.7Hz,2H),4.14–3.99(m ,4H),3.83–3.76(m,3H),3.73(d,J=12.4Hz,1H),3.67–3.60(m,1H),3.42(h,J=6.8Hz,1H),3.21(dt,J=12.4,7.1Hz,1H),3.11 (dt,J=12.4,7.0Hz,1H),2.95(ddd,J=12.4,7.0,1.0Hz,1H),2.75(ddd,J=12.5,7.1,1.1Hz,1H),2.72–2.64(m,4H),2.56(td, J=7.0,2.1Hz,4H),2.30(td,J=7.1,1.8Hz,4H),1.64–1.44(m,13H),1.47–1.34(m,5H),1.37–1.15(m,30H),0.94–0.84(m,6H).
[0127] (4) Compound 20 (A5-B14): Tetrahydroberberine was used to replace tetrahydrobamazine in Example 10 to obtain Compound 20, which 1 HNMR (400 MHz, DMSO-d 6 )δ6.96(dt,J=7.4,1.0Hz,1H),6.90(d,J=7.5Hz,1H),6.72(s,1H),6.57(t,J=1.0Hz,1H),5.97(d,J=3.7Hz,2H),4.14–3.99(m ,4H),3.83–3.76(m,3H),3.73(d,J=12.4Hz,1H),3.67–3.60(m,1H),3.42(h,J=6.8Hz,1H),3.21(dt,J=12.4,7.1Hz,1H),3.11 (dt,J=12.4,7.0Hz,1H),2.95(ddd,J=12.4,7.0,1.0Hz,1H),2.75(ddd,J=12.5,7.1,1.1Hz,1H),2.72–2.64(m,4H),2.56(td, J=7.0,2.1Hz,4H),2.30(td,J=7.1,1.8Hz,4H),1.64–1.44(m,13H),1.47–1.34(m,5H),1.37–1.15(m,30H),0.94–0.84(m,6H).
[0128] It can be seen from the above Examples 10 and 11 that according to the reaction method of Example 10, the reactant AH in the reaction is A4-H (9-hydroxytetrahydropalmatine) or A5-H (9-hydroxytetrahydroberberine), B-OH is HOCOC a H 2a NHC b H 2b+ 1 OCOC c H 2c+1 、HOCOC a H 2a+1 HONH 2 -C c H 2c+1 N(C d H 2d+1 (OH)C e H 2e+1 ) 2 、HOCOC a H 2a+1 N(C b H 2b+1 OCOC c H 2c+1 ) 2 or HOCOC a H 2a+1 N(C c H 2c-2m-1 ) 2 , a berberine derivative with the structural formula AB can be obtained, wherein the structural formula of A is A4 or A5, and B is -COC a H 2a NHC b H 2b+1 OCOC c H 2c+1 、-COC a H 2a+1 -NH 2 -C c H 2c+1 N(C d H 2d+1 (OH)C e H 2e+1 ) 2 、-COC a H 2a+1 N(C b H 2b+1 OCOC c H 2c+1 ) 2 or -COC a H 2a+1 N(C c H 2c-2m-1 ) 2 .
[0129] Example 12
[0130] Compound 8 (A3-B1) was prepared into lipid nanoparticles (LNPs), and then its relevant physicochemical properties and in vitro and in vivo activities were tested, as follows:
[0131] (1) First, lipid nanoparticles (LNPs) were prepared according to different formulations in Table 1. The specific preparation method was as follows: ionizable lipids, auxiliary lipids (including any one of DOPE, DOPC or DSPC), cholesterol and PEG-DMG were dissolved in an organic solvent according to corresponding molar ratios and mixed, and the mixture was mixed with 6.25 mM sodium acetate buffer (pH = 5) containing siRNA (CUU ACGCUGAGUACU UCGATT) at a ratio of v / v = 3:1 (water: organic solvent) using a microfluidic device, and the mixture was transferred to a dialysis bag and dialyzed overnight with PBS buffer solution (pH = 7.4), and then concentrated using an ultracentrifugal filter. A3-B1 was made into an ionizable lipid and combined with auxiliary lipids, cholesterol and PEG-DMG to form different lipid nanoparticles (LNPs) based on A3-B1 (respectively A3-B1-1 to A3-B1-27), and their particle sizes and PDI (polymer dispersibility index) are shown in Table 2. As can be seen from Table 2, the LNP particle size prepared under the formulation No. 10 is <100 nm, and the dispersion is good. It has brain targeting potential in terms of particle size and can be used for subsequent experiments.
[0132] Compounds 1 to 20 prepared in the above examples were prepared according to the formulation No. 10 in Table 1 to obtain lipid nanoparticles (LNPs) formed by different ionizable lipids in the same formulation, and the particle size and PDI (polymer dispersibility index) are shown in Table 3. As can be seen from Table 3, the LNP particle size prepared by some berberine compounds is <100 nm, and the dispersion is good, which has brain targeting potential in terms of particle size, and can be used for subsequent experiments.
[0133] Table 1 Lipid nanoparticles (LNP) with different molar ratios
[0134]
[0135]
[0136] Table 2 Particle size and PDI of different lipid nanoparticles (LNP)
[0137]
[0138] Table 3 Particle size and PDI of lipid nanoparticles (LNPs) formed by different ionizable lipids in the same formulation
[0139]
[0140]
[0141] (2) Compound 6 (A2-B13) prepared in the above example was used as an ionizable lipid and lipid nanoparticles (LNP) were prepared according to the formulation 10 in Table 1. The results were as follows: Figure 1 As shown. Figure 1 It can be seen that the particle size of the lipid nanoparticle LNP-siRNA (A2-B13-10) prepared by compound 6 (A2-B13) is about 100 nm.
[0142] (3) Compound 2 (A1-B13) prepared in the above example was used as an ionizable lipid and lipid nanoparticles (A1-B13-10) were prepared according to the recipe of number 10 in Table 1; Compound 3 (A1-B15) was used as an ionizable lipid and lipid nanoparticles (A1-B15-10) were prepared according to the recipe of number 10 in Table 1; Compound 6 (A2-B13) was used as an ionizable lipid and lipid nanoparticles (A2-B13-10) were prepared according to the recipe of number 10 in Table 1; Compound 7 (A2-B15) was used as an ionizable lipid; lipid, lipid nanoparticles (A2-B15-10) prepared according to the recipe of label 10 in Table 1, lipid nanoparticles (A3-B1-10) prepared according to the recipe of label 10 in Table 1 using compound 8 (A3-B1) as ionizable lipid, lipid nanoparticles (A3-B2-10) prepared according to the recipe of label 10 in Table 1 using compound 9 (A3-B2) as ionizable lipid, lipid nanoparticles (A3-B3-10) prepared according to the recipe of label 10 in Table 1 , lipid nanoparticles (A3-B8-10) were prepared by using compound 12 (A3-B8) as an ionizable lipid and according to the recipe of number 10 in Table 1, lipid nanoparticles (A3-B11-10) were prepared by using compound 13 (A3-B11) as an ionizable lipid and according to the recipe of number 10 in Table 1, lipid nanoparticles (A3-B12-10) were prepared by using compound 14 (A3-B12) as an ionizable lipid and according to the recipe of number 10 in Table 1, and lipid nanoparticles (A3-B12-10) were prepared by using compound 17 (A4-B14) as an ionizable lipid and according to the recipe of number 10 in Table 1. The lipid nanoparticles (A4-B14-10) were prepared by using compound 18 (A4-B15) as the ionizable lipid and the prescription of number 10 in Table 1, the lipid nanoparticles (A4-B15-10) were prepared by using compound 18 (A4-B15) as the ionizable lipid and the prescription of number 10 in Table 1, the lipid nanoparticles (A5-B13-10) were prepared by using compound 19 (A5-B13) as the ionizable lipid and the prescription of number 10 in Table 1, and the lipid nanoparticles (A5-B14-10) were prepared by using compound 20 (A5-B14) as the ionizable lipid and the prescription of number 10 in Table 1.The pka of the lipid nanoparticles prepared by the berberine derivatives was determined by TNS fluorescence method (the specific method is: the prepared lipid nanoparticles were diluted to 2 mM in PBS buffer solution, a buffer containing 130 mM NaCl, 10 mM ammonium acetate, 10 mM Hepes and 10 mM MES was prepared, the lipid nanoparticles were diluted to 100 μM, and the buffer was divided into 8 groups, and the pH value of each group of buffer was adjusted to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 using NaOH or HCl solution; the anionic fluorescent dye 2-(p-toluidino)-6-naphthalenesulfonic Acid (TNS) was dissolved in distilled water to form a solution with a concentration of 100 μM, and the final concentration of lipid nanoparticles was adjusted to 1 uM solution. At room temperature, the fluorescence intensity of each group was measured using a multifunctional microplate reader with an excitation wavelength of 321 nm and an emission wavelength of 445 nm, where pKa was defined as the pH value rising to half of the maximum fluorescence intensity). The final results were as follows. Figure 2 As shown. Figure 2 It can be seen that the pka value of LNP prepared by the berberine derivative of the present invention is 6-7, which is conducive to the efficient encapsulation and lysosomal escape of nucleic acids.
[0143] (4) The encapsulation of siRNA by lipid nanoparticles formed by different berberine derivatives in Table 3 was tested, as shown below:
[0144] The quantitative Quant-iT RiboGreen RNAAssay kit was used to detect the concentration of siRNA in the lipid nanoparticles formed by different berberine derivatives in Table 2, and the method was as follows: the dialyzed lipid nanoparticles were diluted into the Tris-EDTA (TE) buffer in the 96-well plate, and the dialyzed lipid nanoparticles were diluted into the TE buffer containing 2% Triton X-100 for 30 minutes, and then the RiboGreen working solution was added to the corresponding wells, and the fluorescence intensity at an excitation wavelength of 485nm and an emission wavelength of 530nm was detected by an ELISA instrument to reflect the amount of free siRNA and dialyzed siRNA; the siRNA concentration was calculated using the siRNA standard curve and then the encapsulation rate was calculated, and the results are shown in Table 4. As can be seen from Table 4, the LNP prepared by the berberine derivatives of the present invention has a good encapsulation rate for nucleic acids, which is higher than 90%.
[0145] Table 4 Encapsulation efficiency of siRNA by lipid nanoparticles prepared with different berberine derivatives
[0146]
[0147]
[0148] (5) Fluorescence determination of the interaction between berberine derivatives (compound 3 (A1-B15), compound 6 (A2-B13), compound 8 (A3-B1), and compound 18 (A4-B15)) and polyA:
[0149] PolyA and berberine derivative solutions were prepared daily and used at a concentration of 10 μM. All reactions were performed in BPES buffer (containing 1.5 mM Na 2 HPO 4 ,0.5mM NaH 2 PO 4 , 0.25 mM EDTA and 6 mM NaCl) or citrate-phosphate (CP) buffer (containing 5 mM Na 2 HPO 4 ), and citric acid was used to adjust the pH to 7.1 and 4.5. The detection was performed on a black 96-well plate multifunctional microplate reader with an excitation wavelength of 350 nm. The results are shown in Figure 3 As shown. Figure 3 It can be seen that berberine derivatives can combine with polyA to form a self-structure.
[0150] (6) Fluorescence microscopy of the in vitro transfection effect of lipid nanoparticles loaded with eGFP mRNA prepared by berberine derivatives:
[0151] bEnd.3 cells were seeded in 6-well plates (with a confluence of 30%) and cultured in 2 mL of complete medium without dual antibodies for 12 hours. The medium was then replaced with serum-free medium without dual antibodies, and lipid nanoparticles loaded with eGFP mRNA (compound 1 (A1-B4), compound 3 (A1-B15), compound 4 (A2-B5), compound 6 (A2-B13), compound 8 (A3-B1), compound 11 (A3-B7), compound 16 (A4-B10), compound 18 (A4-B15), compound 19 (A5-B13) and Lipo2000 (control group) were added to the cells and incubated at 37°C and 5% CO 2 The cells were incubated for 6 h under the environment, and the culture medium was replaced with complete culture medium without dual antibodies. The culture was continued for 18 h, and the fluorescence intensity of the different drug-administered groups was observed under a fluorescence microscope. The results are as follows: Figure 4 As shown. Figure 4 It can be seen that compared with the gold standard cell transfection reagent lipo2000, the LNP prepared by berberine compound can better carry mRNA for transfection into cells.
[0152] (7) MTT assay of the cytotoxicity of lipid nanoparticles formed by different berberine derivatives in Table 2:
[0153] bEnd.3 cells were seeded in 96-well plates (6000 cells per well) and cultured in 100 μL of culture medium for 12 h. Afterwards, lipid nanoparticles formed by different berberine derivatives in Table 2 were added to the cells and incubated at 37°C and 5% CO 2 Incubate for 48 hours at room temperature; at the end of the experiment, add 3-(4,5)-dimethylthiazolylazo (-z-y1)-3,5-diphenyltetrazolium urea (MTT) solution (5 mg / ml, 20 μL), and further culture at 37°C for 4 hours, then remove the culture medium, add 150 μL of DMSO, and shake at room temperature for 10 minutes. The cell viability is calculated by measuring the absorbance of each well at 570 nm using an ELISA reader. The results are shown in Figure 5 As shown. Figure 5 It can be seen that the LNP prepared from the berberine derivatives of the present invention has low cytotoxicity and high biocompatibility.
[0154] (8) Taking the lipid nanoparticles encapsulated with siRNA formed by berberine derivatives (A2-B13) in Table 2 as an example, the N / P ratio was determined by gel retardation experiment:
[0155] siRNA (1OD) was dissolved in 125μL DEPC water, and lipid nanoparticles (LNP) formed by berberine derivative compound 1 (A2-B13) in Table 2 and siRNA solution were mixed at siRNA / LNP mass ratios of 5:1, 1:1, 1:2, 10:1, 1:5, 1:10, 1:15, and 1:20, respectively. The mixture was incubated at room temperature for 30 minutes; the siRNA binding ability of LNP was investigated by agarose gel electrophoresis; it was mixed with 6× loading buffer, and after mixing, it was added to 2% agarose gel containing 0.01% gel stain Glodview; electrophoresis was performed in 1×TAE buffer under ice bath conditions, the voltage was 180V, and the electrophoresis was performed for 20 minutes. The results were recorded at a UV wavelength of 320nm using a gel image analysis system (Tanon, China), and the results are shown in FIG. Figure 6 As shown. Figure 6 It can be seen that the LNP prepared from the berberine derivative of the present invention can completely encapsulate siRNA when the siRNA / LNP mass ratio is greater than 1:5.
[0156] (9) Confocal microscopy was used to photograph the endosomal escape effect of lipid nanoparticles loaded with siRNA formed by different berberine derivatives in Table 2 (compound 3 (A1-B15), compound 6 (A2-B13) and compound 8 (A3-B1) as examples):
[0157] bEnd.3 cells were seeded in 12-well plates (20,000 cells per well) and cultured in 500 μL of culture medium for 12 h. The culture medium in the wells was discarded and replaced with new complete culture medium. LNP@FAM-siRNA (lipid nanoparticles formed by different berberine derivatives in Table 2) was added to the cells and incubated at 37°C and 5% CO. 2 After transfection, the culture medium containing LNP (lipid nanoparticles formed by different berberine derivatives in Table 2 (compound 3 (A1-B15), compound 6 (A2-B13) and compound 8 (A3-B1) as examples)) was discarded, washed 3 times with PBS buffer solution, incubated with Lysotracker Red (1uM) at 37°C in the dark for 2h, discarded the supernatant after incubation, added PBS buffer solution to rinse 3 times, fixed the cells with 4% paraformaldehyde fixative at room temperature for 30min, discarded the fixative and added PBS buffer solution to rinse 3 times, added DAPI cell nuclear stain solution to incubate in the dark for 10min, rinsed 3 times with PBS buffer solution, and then used a high-content imaging system to perform fluorescence co-localization photography in confocal mode. The results are shown in FIG. Figure 7 As shown. Figure 7 It can be seen that the LNP prepared from the berberine derivative of the present invention can carry siRNA and efficiently escape from lysosomes.
[0158] Embodiment 13
[0159] Preparation of a berberine derivative (Compound 21 (A2-B16)), specifically comprising the following steps:
[0160] (1) COOH-PEG 2000 -DSPE (60 mg, 0.02 mmol) (mass spectrum as shown Figure 8 As shown in a), A2-H (tetrahydroafricanine) (13 mg, 0.04 mmol), benzotriazol-1-yl-oxytripyrrolidinophosphine hexafluorophosphate (PyBop, 31.2 mg, 0.06 mmol) were dissolved in 3 mL of N,N-dimethylformamide, and the reaction mixture was stirred at room temperature for 24 h;
[0161] (2) The reaction solution was placed in a dialysis bag and dialyzed with pure water for 24 hours. The aqueous solution in the dialysis bag was taken out and freeze-dried to obtain the structural formula A2-PEG 2000 The berberine derivative of -DSPE is compound 21 (A2-B16) (its mass spectrum is shown in Figure 8 (as shown in b).
[0162] It can be seen that according to the preparation method of Example 13, HOCO-PEG-DSPE with different polymerization degrees is reacted with A2-H (tetrahydroafricanine) to obtain a compound with the structural formula AB, wherein A is A2 and B is -PEG-DSPE.
[0163] Embodiment 14
[0164] Fluorescence microscopy was used to photograph the in vitro brain targeting of berberine derivatives (compound 3 (A1-B15), compound 6 (A2-B13), compound 8 (A3-B1), compound 18 (A4-B15), compound 19 (A5-B13), and compound 21 (A2-B16) as examples):
[0165] bEnd.3 cells were seeded in a 12-well plate (confluence was 50%) and cultured in 1 mL of complete medium for 12 h. Then, lipid nanoparticles loaded with DiD fluorescence (compounds 3 (A1-B15), compound 6 (A2-B13), compound 8 (A3-B1), compound 18 (A4-B15), compound 19 (A5-B13), compound 21 (A2-B16) and a conventional preparation (control group) were added to the cells and incubated at 37°C and 5% CO 2 The cells were incubated for 2 h under the environment, and the fluorescence intensity of DiD in different drug administration groups was observed under a fluorescence microscope. The results are as follows: Fig. 9 As shown. Fig. 9 It can be seen that compared with lipid nanoparticles prepared without berberine derivatives, LNPs prepared with berberine derivatives can be better taken up by cells.
[0166] Embodiment 15
[0167] Flow cytometry was used to detect the in vitro brain targeting mechanism of berberine derivatives (compound 6 (A2-B13)):
[0168] bEnd.3 and DRD3 - / - bEnd.3 cells were seeded in 12-well plates (confluence was 50%) and cultured in 1 mL of complete medium for 12 h. DiD fluorescent lipid nanoparticles (compound 6 (A2-B13)) and conventional preparations (control group) were then added to the cells and incubated at 37°C and 5% CO 2 Incubate for 2 h at room temperature, remove the culture medium, wash three times with PBS, digest the cells with trypsin, resuspend with 500uL PBS, and use flow cytometry to detect the uptake of the preparation by bEnd.3 cells before and after dopamine receptor silencing. The results are as follows: Fig.10 As shown. Fig.10It can be seen that compared with the uptake of the preparation by bEnd.3 cells, the uptake of the preparation by bEnd.3 cells after dopamine receptor silencing was greatly reduced, indicating that the dopamine receptor DRD3 may mediate the internalization of LNPs prepared by berberine derivatives.
[0169] The reason why compound 3 has in vitro brain targeting is that it has an isoquinoline cyclic core and oxygen-containing or nitrogen-containing groups on the side chains, which can target the DRD3 receptors on cerebral vascular endothelial cells in vitro. Similarly, other compounds (such as compound 3 (A1-B15), compound 8 (A3-B1), compound 18 (A4-B15), and compound 19 (A5-B13)) have isoquinoline cyclic groups and oxygen-containing or nitrogen-containing groups on the side chains, which can also interact with the DRD3 receptors in in vitro brain targeting. Therefore, it is shown that other compounds (such as compound 3 (A1-B15), compound 8 (A3-B1), compound 18 (A4-B15), and compound 19 (A5-B13)) also have in vitro brain targeting.
[0170] Example 16
[0171] In vivo imaging was used to capture the in vivo brain targeting of berberine derivatives (compound 3 (A1-B15), compound 6 (A2-B13), compound 8 (A3-B1), compound 18 (A4-B15), and compound 19 (A5-B13) as examples):
[0172] The DiR-loaded preparations (compounds 3 (A1-B15), compound 6 (A2-B13), compound 8 (A3-B1), compound 18 (A4-B15), and compound 19 (A5-B13)) were injected into mice via the tail vein, and fluorescence images were collected at predetermined time points (0.5, 1, and 2 h) using the VISQUE in vivoSmart-LF System. The results are shown in Figure 2. Fig.11 As shown. Fig.11 It can be seen that, compared with the control group (Control), the berberine derivatives of the present invention have brain targeting properties.
[0173] Embodiment 17
[0174] In vivo imaging was used to investigate the in vivo brain targeting of berberine derivatives combined with scutellarin, gallic acid, and citric acid:
[0175] The DiR-loaded preparation (LNP prepared from compound 6 (A2-B13)) was combined with scutellarin, gallic acid, and citric acid and injected into mice via the tail vein. Fluorescence images were collected at predetermined time points (2, 6 h) using the VISQUE in vivo Smart-LF System. The results are shown in Figure 2. Fig.12 As shown. Fig.12 It can be seen that compared with the berberine derivative group without organic acid, the berberine derivative of the present invention has stronger brain targeting after being combined with scutellarin, gallic acid and citric acid.
[0176] The reason why compound 3 has stronger in vivo brain targeting after being combined with organic acids (such as scutellariae, gallic acid, and citric acid) is that it has an isoquinoline cyclic core and nitrogen-containing groups on the side chains, which can be paired with organic acids in in vivo brain targeting to improve in vivo distribution. Similarly, other compounds (such as compound 3 (A1-B15), compound 8 (A3-B1), compound 18 (A4-B15), and compound 19 (A5-B13)) have isoquinoline cyclic groups and nitrogen-containing groups on the side chains, which can also be paired with organic acids in in vivo brain targeting to improve in vivo distribution. Therefore, it is shown that other compounds (such as compound 3 (A1-B15), compound 8 (A3-B1), compound 18 (A4-B15), and compound 19 (A5-B13)) also have stronger in vivo brain targeting after being combined with organic acids.
[0177] Similarly, the following conclusions can be drawn from Examples 1 to 10 and 13: a berberine derivative can be prepared by the preparation method of the present invention, and the structural formula of the berberine derivative is AB, wherein the structural formula of A is any one of A1 to A5, and B is -C a H 2a-2m-1 、-COC a H 2a-2m-2 , C b H 2b+1 OCO(CH 2 ) y -, XC a H 2a CO-、-C a H 2a+1 OC c H 2c+1 Ph, -C a H 2a+1 NHCOC b H 2b-1 , -C a H 2a+1 COOH, -COC a H 2a NHC b H 2b+1 OCOC c H 2c+1 、-COC a H 2a+ 1 NHC c H 2c-2m-1 、-COC a H2a+1 (NH 2 )C c H 2c+1 NHC d H 2d+1 (OH)C e H 2e+1 、-COC a H 2a+1 (NH 2 )C c H 2c+1 N(C d H 2d+1 (OH)C e H 2e+1 ) 2 、-COC a H 2a+1 N(C b H 2b+1 OCOC c H 2c+1 ) 2 、-COC a H 2a+1 N(C c H 2c-2m-1 ) 2 Or any one of DSPE-PEG- (wherein a is an integer of 10 to 18, b is an integer of 10 to 18, c is an integer of 10 to 18, d is an integer of 10 to 18, e is an integer of 10 to 18, Ph is a benzene ring, X is a halogen, and m is the number of carbon-carbon double bonds), and the prepared berberine derivative can be used as an ionizable lipid to construct a safe and efficient brain-targeted delivery system for nucleic acid drugs, and has good application prospects in brain-targeted drug delivery and nucleic acid delivery.
[0178] In summary: The present invention discloses berberine derivatives and their preparation methods and applications. After comprehensive verification from molecular research to animal experiments, it is found that the berberine derivatives disclosed in the present invention show the following advantages: (i) they have strong nucleic acid carrying capacity and can improve nucleic acid stability by forming self-structures; (ii) they are particularly conducive to the escape of nucleic acid drugs from lysosomes and improve intracellular transport; (iii) in vitro, they show super brain targeting properties in a specific manner, and they also show the same trend in vivo (mainly due to active targeting mediated by dopamine receptors). Therefore, the berberine derivatives disclosed in the present invention can be used as an ionizable lipid to construct a safe and efficient nucleic acid drug brain targeting delivery system.
[0179] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the purpose and scope of the technical solution, which should be included in the scope of the claims of the present invention.
Claims
1. Berberine derivatives, It is characterized in that The structural formula of the berberine derivative is AB, The structural formula of A is any one of A1 to A5: ; Any one of the structural formulas of B1, B3~B7, B9, B10, B13~B15: 。 2. The berberine derivative according to claim 1, It is characterized in that The berberine derivative includes any one of Compound 1 to Compound 7, Compound 11, Compound 15 to Compound 20: 。 3. A method for preparing the berberine derivative according to any one of claims 1 to 2, It is characterized in that The preparation method comprises the following steps: When the structural formula of A is A1 or A2, and B is B1, B4 or B5, the preparation method is as described in the following method 1: AH and BX are dissolved in N,N-dimethylformamide, potassium carbonate and potassium iodide are added, and the mixture is stirred at room temperature for 12 to 36 hours under a nitrogen atmosphere, and the reaction is monitored by thin layer chromatography. After the reaction is completed, the mixture is filtered and concentrated under vacuum, and purified by column chromatography; When the structural formula of A is A1 or A2, and B is B3, B13 or B15, the preparation method is as described in the following method 2: B-OH is dissolved in dry dichloromethane, N,N-dicyclohexylcarbodiimide and methylaminopyridine p-toluenesulfonate are added, and the mixture is stirred and reacted at room temperature under a nitrogen atmosphere for 0.5 to 1 h to obtain a reaction mixture, AH is dissolved in N,N-dimethylformamide and then added dropwise to the reaction mixture, and the mixture is reacted at room temperature under a nitrogen atmosphere for 24 to 48 h, and the reaction is monitored by thin layer chromatography. After the reaction is completed, the mixture is filtered and concentrated under vacuum, and purified by column chromatography; When the structural formula of A is A3, and B is B1 or B7, the preparation method is as described in the following method 3: 2,3-dihydroxytetrahydroberberine and BX are dissolved in N,N-dimethylformamide to form a reaction mixture, potassium carbonate and potassium iodide are added, and the mixture is stirred at room temperature under a nitrogen atmosphere for 12 to 36 hours, and the reaction is monitored by thin layer chromatography. After the reaction is completed, the mixture is filtered and concentrated under vacuum, and purified by column chromatography; When the structural formula of A is A3 and B is B3, the preparation method is as described in the following method 4: B-OH is dissolved in dry dichloromethane, N,N-dicyclohexylcarbodiimide and dimethylaminopyridine p-toluenesulfonate are added, and the mixture is stirred at room temperature for 30 minutes under a nitrogen atmosphere to obtain a reaction mixture, 2,3-dihydroxytetrahydroberberine is dissolved in N,N-dimethylformamide and then added dropwise to the reaction mixture, and the mixture is stirred at room temperature for 24 to 48 hours under a nitrogen atmosphere, and the reaction is monitored by thin layer chromatography. After the reaction is completed, the mixture is filtered and concentrated under vacuum, and purified by column chromatography; When the structural formula of A is A4 and B is B9, the preparation method is as described in the following method 5: tetrahydrobamipine (33 mg, 0.1 mmol) is placed in a thermal decomposition reactor and reacted at 190° C. for 2 h to obtain 9-hydroxytetrahydrobamipine, 9-hydroxytetrahydrobamipine and 8-bromooctanoic acid (78 mg, 0.35 mmol) are dissolved in N,N-dimethylformamide (30 mL) to form a reaction mixture, potassium carbonate (42 mg, 0.3 mmol) and potassium iodide (2 mg, 0.01 mmol) are added, and the mixture is stirred for 16 h under a nitrogen atmosphere at room temperature, and the reaction is monitored by thin layer chromatography. After the reaction is completed, the mixture is filtered and concentrated under vacuum, and purified by column chromatography to obtain compound 15; When the structural formula of A is A4 or A5, and B is B10, B13, B14 or B15, the preparation method is as described in the following method 6: B-OH is dissolved in dry dichloromethane, N,N-dicyclohexylcarbodiimide and dimethylaminopyridine p-toluenesulfonate are added, and the mixture is stirred for 0.5 to 1 h under nitrogen atmosphere at room temperature, 9-hydroxytetrahydropalmatine or 9-hydroxytetrahydroberberine is dissolved in N,N-dimethylformamide and then added dropwise to the reaction mixture, and the mixture is stirred at room temperature and under nitrogen atmosphere for 24 to 48 h, and the reaction is monitored by thin layer chromatography. After the reaction is completed, the mixture is filtered and concentrated under vacuum, and purified by column chromatography. Wherein X is a halogen.
4. The preparation method according to claim 3, It is characterized in that The eluent used in the column chromatography purification is a mixed solution composed of methanol and dichloromethane in a volume ratio of 10:90 to 90:
10.
5. The preparation method according to claim 3, It is characterized in that In method 1, the molar ratio of AH, BX, potassium carbonate and potassium iodide is 0.1:0.35:0.3:0.01; In method 2, the molar ratio of AH, B-OH, N,N-dicyclohexylcarbodiimide and methylaminopyridine p-toluenesulfonate is 0.1:0.35:0.6:0.06; In method 3, the molar ratio of 2,3-dihydroxytetrahydroberberine, BX, potassium carbonate and potassium iodide is 0.1:0.35:0.3:0.01; In method 5, the molar ratio of 9-hydroxytetrahydropalmatine, 8-bromooctanoic acid, potassium carbonate and potassium iodide is 0.1:0.35:0.3:0.01; In method six, the molar ratio of 9-hydroxytetrahydropalmatine or 9-hydroxytetrahydroberberine, B-OH, N,N-dicyclohexylcarbodiimide and dimethylaminopyridine p-toluenesulfonate is 0.1:0.4:0.6:0.6; Wherein X is a halogen.
6. The preparation method according to claim 3, It is characterized in that In method three, the 2,3-dihydroxytetrahydroberberine is prepared according to the following method: tetrahydroberberine is dissolved in dry dichloromethane at 0°C, stirred and dissolved under a nitrogen atmosphere, and then a n-hexane solution containing boron trichloride is added, stirred at 0°C for 0.5~1 h, and then stirred at room temperature for 4~6 h, and the reaction is quenched with miliQ water for 0.5~2 h; concentrated under vacuum, purified by column chromatography, and 2,3-dihydroxytetrahydroberberine is obtained.
7. The preparation method according to claim 3, It is characterized in that In method five, the 9-hydroxytetrahydrobamipine is prepared as follows: tetrahydrobamipine is placed in a pyrolysis reactor and reacted at 180-200° C. for 1-4 h to obtain 9-hydroxytetrahydrobamipine.
8. Use of the berberine derivative according to any one of claims 1 to 2 in the preparation of brain-targeted drug delivery materials.
9. Use of the berberine derivative according to any one of claims 1 to 2 in the preparation of nucleic acid delivery materials.
